Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Demands Cake, Bite

NEW YORK, Dec. 16 - Incyte Genomics will change its name next year to Incyte Corporation.


The company, which changed its name to Incyte Genomics from Incyte Pharmaceuticals two years ago, said its latest re-christening is designed to reflect a "broader mission" as a company devoted to discovering drugs and selling discovery tools.


"This decision was driven by the desire to unify our genomic and proteomic information business, intellectual property and rapidly growing drug discovery organization under the Incyte name," CEO Paul Friedman said without irony. "We believe the name change will help position the company better among our customers, collaborators, stockholders and employees as an emerging drug discovery company."


Incyte said it also will "launch a new graphic look" and web site next year "to reflect the new corporate identity."


The name change is the latest step in Incyte's slow metamorphosis into a drug company--in this case, a drug company that also happens to sell tools.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.